ClinicalTrials.gg
Not yet recruitingNCT06926998Updated Apr 15, 2025

9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors

A Phase 1/2 interventional study of 9MW2821+other anticancer therapy in Gynecological Malignancies, sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-15.

Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
260
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Study summary

To evaluate the safety, tolerability, and preliminary efficacy of 9MW2821 in combination with other anti-tumor agents in patients with advanced gynecological malignancies.

02

Conditions studied

  • Gynecological Malignancies
03

In context

Lead sponsor

Mabwell (Shanghai) Bioscience Co., Ltd. is the lead sponsor of 54 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Competent to comprehend, sign, and date an independent ethics committee/institutional review board/research ethics board (IEC/IRB/REB) approved form.
  2. Female subjects aged 18 to 75 years (including 18 and 75 years).
  3. (ECOG) performance status of 0 or 1.
  4. Histopathological diagnosed of advanced gynecological tumors.
  5. Subjects must submit tumor tissues for test.
  6. of ≥ 12 weeks.
  7. Subjects must have according to (version 1.1).
  8. Adequate organ functions.
  9. Sexually active fertile subjects must agree to use methods of during the study and at least 180 days after termination of study therapy.
  10. Subjects are willing to follow study procedures.

Exclusion criteria

Exclusion Criteria:

  1. History of another within 3 years before the first dose of study drug.
  2. Patients with ongoing toxicities related to prior treatment.
  3. Presence of Grade ≥ 2 peripheral neuropathy.
  4. Exclusion of prior diseases and prior treatments as specified in the protocol.
  5. Comorbidities: a. ≥ 8%; b. Ocular diseases or symptoms present prior to the first dose of study medication; c. Severe respiratory diseases; d. Clinically significant cardiovascular or cerebrovascular diseases within 6 months prior to the first dose of study medication; e. Active diseases within 2 years prior to the first dose of study medication, or a history of autoimmune diseases with potential for recurrence; f. Active infections; g. Severe arterial or venous thromboembolic events.
  6. Clinically significant bleeding symptoms or a clear bleeding tendency within 3 months prior to the first dose of medication.
  7. Subjects with central nervous system (CNS) and/or carcinomatous meningitis.
  8. Pleural, peritoneal, or pericardial effusion with clinical symptoms or requiring repeated drainage procedures.
  9. Prior Treatments: a. Major surgical procedures within 28 days prior to the first dose of study medication; b. Administration of other drugs or experimental medical devices within 28 days prior to the first dose of study medication; c. Use of P-glycoprotein inhibitors or inducers, or potent inhibitors within 14 days prior to the first dose of study medication; d. Receipt of within 28 days prior to the first dose of study medication or planned administration of any live vaccine during the study period; e. Prior hematopoietic stem cell transplantation or solid organ transplantation;.
  10. Subjects with a history of drug abuse or psychiatric disorders, or suspected allergy, intolerance, or severe infusion reactions to the investigational drug or any of its components.
  11. Pregnant or lactating women.
  12. Not suitable to receive study treatment for other conditions as per investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Treatment Cohort

    9MW2821+ other anti-cancer therapy

    Drug: 9MW2821+other anticancer therapy

Interventions

  • Drug9MW2821+other anticancer therapy

    Subjects will receive intravenous (IV) infusion of 9MW2821 +other anticancer therapy as per protocol

06

What researchers measure

Primary outcomes

  1. ORR

    Objective Response Rate

    Time frame: Up to 24 months

Secondary outcomes

  1. DoR

    Duration of Response

    Time frame: Up to 24 months

  2. TTR

    Time to Response

    Time frame: Up to 24 months

  3. DCR

    Disease Control Rate

    Time frame: Up to 24 months

  4. PFS

    Progression Free Survival

    Time frame: Up to 24 months

  5. OS

    Overall Survival

    Time frame: Up to 24 months

  6. Pharmacokinetic parameter:total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE)

    Maximum observed concentration (Cmax)

    Time frame: 24 months

  7. Pharmacokinetic parameter:total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE)

    Area under the concentration-time curve (AUC)

    Time frame: 24 months

  8. Pharmacokinetic parameter:total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE)

    Half-life (t1/2)

    Time frame: 24 months

  9. Pharmacokinetic parameter:total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE)

    Clearance (CL)

    Time frame: 24 months

  10. Incidence of Anti-Drug Antibody (ADA)

    ADA

    Time frame: 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for May 2027, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2025
First posted
Apr 15, 2025
StartEst.
Apr 15, 2025
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2027
Last update
Apr 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06926998
Responsible party
Sponsor
First posted
Apr 15, 2025
Start date
Apr 15, 2025 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Apr 15, 2025

Study contacts

Hanmei Lou, Professor
Contact
louhm@zjcc.org.cn
13355783145
Hanmei Lou, Professor
principal investigator · Zhejiang Cancer Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion